Compare · MDLN vs RMD
MDLN vs RMD
Side-by-side comparison of Medline Inc. (MDLN) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $58.80B, about 1.8x RMD ($32.03B).
- Over the past year, MDLN is up 9.9% and RMD is down 6.1% - MDLN leads by 16.0 points.
- MDLN has been more active in the news (5 items in the past 4 weeks vs 2 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- ResMed Inc.
- Price
- $44.77-3.05%
- $219.82+0.11%
- Market cap
- $58.80B
- $32.03B
- 1M return
- +5.00%
- -2.86%
- 1Y return
- +9.87%
- -6.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest MDLN
- SEC Form DEFA14A filed by Medline Inc.
- SEC Form DEF 14A filed by Medline Inc.
- Medline announces first-in-healthcare AI robotics partnership with Symbotic
- Medline to report first quarter 2026 results on May 6, 2026
- Medline launches custom product fulfillment technology called Pick Pack Pro™
- Medline recognizes manufacturing facilities with Golden Cone Safety Award
- Medline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
- Director Healy Patrick J acquired 577,510 shares, increasing direct ownership by 73% to 1,208,159 units (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,058,524,148 worth of shares (26,131,237 units at $40.51) and disposed of 2,088,086 shares (SEC Form 4)
- Large owner Cp Circle Ml Holdco Gp, Llc sold $1,070,339,440 worth of shares (26,105,840 units at $41.00) and disposed of 2,113,483 shares (SEC Form 4)
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.